Nxera Pharma Ltd
Tokyo, Tokyo, Japan · Biotechnology, Pharmaceutical
Nxera Pharma (formerly Sosei Heptares) is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. In addition to several products being commercialized in Japan, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnershi
Key facts
- Headquarters
- Tokyo, Tokyo, Japan
- Employees
- 390
- Industries
- Biotechnology, Pharmaceutical
- Website
- www.nxera.life
- Company page
Recent activity at Nxera Pharma Ltd
- : Nxera Pharma secured a $10 million milestone payment from Neurocrine Biosciences following IND acceptance for NBI-1117567 in a Phase 2 study. This funding will enhance Nxera's drug development initiatives.
- : Nxera Pharma has participated in a Series A financing for NewCo, a company it co-founded, to accelerate preclinical studies of a GPCR-targeted program. Nxera is eligible for up to $275 million in milestone payments.
- : Nxera Pharma Appoints Kiyoshi Kaneko as Chief Commercial Officer and Promotes Mariko Nakafuji to Chief Legal Officer
- : Nxera Pharma Announces Appointments to Executive Leadership Team
- : Centessa Initiates Phase 2 Trial with ORX750, Resulting in US$3.5 Million Milestone Payment to Nxera Pharma
- : Nxera Pharma Co., Ltd. appoints Dr. Makoto Sugita as President of Nxera Pharma Japan and Executive Vice President and CMO
Nxera Pharma Ltd funding history
| Date | Round | Amount |
|---|---|---|
| May 2026 | Series A | $275.0M |
Leadership
- Mariko Nakafuji, Chief Legal Officer
- Kiyoshi Kaneko, Chief Commercial Officer
- Makoto Sugita, President
- Nigel Austin, Chief Technology Officer
- Hironoshin Nomura, Chief Financial Officer
Verified email and direct lines for Nxera Pharma Ltd’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Nxera Pharma Ltd in the news
- Nxera Pharma’s Partner Neurocrine Biosciences Receives IND - GlobeNewswire (Aug 26, 2026)
- Nxera Pharma’s Partner Centessa Pharmaceuticals to be Acquired by Lilly - GlobeNewswire (Mar 31, 2026)
- Nxera Announces Successful Resolution of miniG Patent Infringement Action - GlobeNewswire (Oct 01, 2026)
- Nxera Pharma Announces Progress of Out-Licensing of - GlobeNewswire (May 11, 2026)
- Nxera Pharma to Receive $8.6 Million Milestone Payment from - GlobeNewswire (Sep 03, 2026)
- Nxera Joins OpenFold AI Research Consortium Alongside - GlobeNewswire (Jun 10, 2026)
- Nxera Announces Focused Restructuring to Enhance Path to Profitability - GlobeNewswire (Nov 17, 2025)
- Nxera Pharma is the New Name for Sosei Group - GlobeNewswire (Mar 31, 2024)
Companies similar to Nxera Pharma Ltd
- Crinetics Pharmaceuticals · Biotechnology, Pharmaceutical
- Envirotainer · Biotechnology, Pharmaceutical
- Amylyx Pharmaceuticals · Biotechnology, Pharmaceutical
- Pharming Group · Biotechnology, Pharmaceutical
- PCCA · Biotechnology, Pharmaceutical
About Nxera Pharma Ltd: questions and answers
What does Nxera Pharma Ltd do?
Nxera Pharma (formerly Sosei Heptares) is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. In addition to several products being commercialized in Japan, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnershi
Where is Nxera Pharma Ltd headquartered?
Nxera Pharma Ltd is headquartered in Tokyo, Tokyo, Japan.
How many employees does Nxera Pharma Ltd have?
Nxera Pharma Ltd has about 390 employees.
Has Nxera Pharma Ltd raised funding?
Yes. Fundz has recorded 1 funding event for Nxera Pharma Ltd. The most recent, Series A of $275.0M, was in May 2026.
Who leads Nxera Pharma Ltd?
Makoto Sugita is a President at Nxera Pharma Ltd.
What is the latest news on Nxera Pharma Ltd?
On Aug 26, 2026, Nxera Pharma secured a $10 million milestone payment from Neurocrine Biosciences following IND acceptance for NBI-1117567 in a Phase 2 study. This funding will enhance Nxera's drug development initiatives.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy